• 14 January 2010

    BIOTRONIK SE & Co. KG, a leading manufacturer of implantable cardiac devices and pioneer of wireless remote monitoring technologies and Endosense, a Swiss medical technology company, today announced that they have entered into an exclusive distribution agreement for Endosense’s force-sensing ablation catheter, the TactiCath®. Under the terms of the agreement, BIOTRONIK will be the exclusive distributor of the TactiCath in all major markets outside of the United States, Japan and Asia.

  • 23 December 2009

    Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial drug resistance, announces today that its shareholders have signed a definitive agreement whereby Novexel shall be acquired by AstraZeneca for a total cash consideration of up to $505 million, including contingent payments and the net cash position of the company at closing. The transaction is expected to close in the first quarter of 2010, subject to certain customary conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976.

  • 10 December 2009

    Endosense, a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced the appointment of health-care industry veterans Jan H. Egberts, M.D. and Michael J. Dormer, to new chairman of the board and board director, respectively. Representing several decades of senior management experience at industry-leading medical device and pharmaceutical companies, the two join Endosense as it pursues the European commercialization and U.S. Premarket Approval (PMA) clinical study of the company’s proprietary force-sensing ablation catheter, the TactiCath®.

  • 2 December 2009

    NovaShunt today announced the appointment of Dr. Pedro Eerdmans as Chief Medical Officer and Dan Rose as Vice President of Commercial Operations and member of the Company’s Board of Directors.

  • 5 October 2009

    Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharmaceutical company focused on orphan neuromuscular diseases, announced today the final closing of the acquisition of Oy Juvantia Pharma Ltd of Turku, Finland. Santhera issued 105,973 previously reserved shares from its authorized share capital to Juvantia investors, as announced when exercising its option to acquire Juvantia on August 17, 2009. The closing of the transaction triggers a final upfront payment of USD 4 million from Biovail Laboratories International SRL, a sububsidiary of Biovail Corporation, Santhera's licensing partner for the further development and marketing of JP-1730/fipamezole to treat Dyskinesia in Parkinson's Disease in the United States and Canada.